Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Macy's, Inc.M · Entity 3820 | SVP,Controller/ERM & Int. CFO | July 09, 2020 | July 10, 2020 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2026 | June 03, 2026 |
| Paycom Software, Inc.PAYC · Entity 3498 | Director | May 05, 2025 | May 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Macy's, Inc.
Report date July 09, 2020 · Filed July 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,790 |
Reported balance
After 2020-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-09 · Grant · Acquired 52,790 · Balance 52,790 F1: Each restricted stock unit represents the equivalent of one share of the Issuer's common stock. F2: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the equivalent of one share of the Issuer's common stock.
F2: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted.
NEOGENOMICS INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,237 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 23,077 · Balance 30,237 F1: Reflects release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 23,077 · Balance 0 F2: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,970 |
Reported balance
After 2026-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-01 · Grant · Acquired 15,970 · Balance 15,970 F2: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01 | Direct | 11,069 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 11,069 · Balance 11,069 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.59 · Expires 2034-06-01 | Direct | 5,430 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 5,430 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.28 · Expires 2035-06-01 | Direct | 16,107 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 16,107 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: Once vested, the shares of common stock are not subject to expiration.
Paycom Software, Inc.
Report date May 05, 2025 · Filed May 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,706 |
Reported balance
After 2025-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-05 · Grant · Acquired 1,099 · Balance 3,706 F1: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan. F2: Includes 2,315 unvested shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan.
F2: Includes 2,315 unvested shares of restricted stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Anywhere Real Estate Inc.
Report date January 09, 2026 · Filed January 09, 2026
Section 16 reporting ended · disclosed 2026-01-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-09 transaction · row 1
1 source rowRow 1 · 2026-01-09 · Disposition to issuer · Disposed 134,617 · Balance 0 F1: On January 9, 2026, pursuant to the previously announced Agreement and Plan of Merger, dated as of September 22, 2025 (the Merger Agreement), by and among Anywhere Real Estate Inc. (the Company), Compass, Inc. (Compass), and Velocity Merger Sub, Inc., a wholly owned subsidiary of Compass (Merger Sub), Merger Sub merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly owned subsidiary of Compass. F2: Pursuant to the Merger Agreement, each share of Company common stock, par value $0.01 per share issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), was converted into the right to receive 1.436 fully paid and nonassessable shares (the Exchange Ratio) of class A common stock of Compass (the Compass Shares) and, if applicable, cash in lieu of fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU award was canceled and converted into a RSU award in respect of Compass Shares covering that number of Compass Shares equal to the product of (i) the number of shares of Company common stock subject to the award multiplied by (ii) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 9, 2026, pursuant to the previously announced Agreement and Plan of Merger, dated as of September 22, 2025 (the Merger Agreement), by and among Anywhere Real Estate Inc. (the Company), Compass, Inc. (Compass), and Velocity Merger Sub, Inc., a wholly owned subsidiary of Compass (Merger Sub), Merger Sub merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly owned subsidiary of Compass.
F2: Pursuant to the Merger Agreement, each share of Company common stock, par value $0.01 per share issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), was converted into the right to receive 1.436 fully paid and nonassessable shares (the Exchange Ratio) of class A common stock of Compass (the Compass Shares) and, if applicable, cash in lieu of fractional shares.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU award was canceled and converted into a RSU award in respect of Compass Shares covering that number of Compass Shares equal to the product of (i) the number of shares of Company common stock subject to the award multiplied by (ii) the Exchange Ratio.
MERIDIAN BIOSCIENCE INC
Report date January 31, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Disposition to issuer · Disposed 10,274 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.15 · Expires 2028-09-20 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-31 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.97 · Expires 2029-01-04 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-31 · Disposition to issuer · Disposed 8,740 · Balance 0 F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.46 · Expires 2030-01-29 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-31 · Disposition to issuer · Disposed 17,205 · Balance 0 F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.36 · Expires 2031-01-27 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-31 · Disposition to issuer · Disposed 5,796 · Balance 0 F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2032-01-26 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-01-31 · Disposition to issuer · Disposed 5,656 · Balance 0 F6: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F6: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 23:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 15,970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040579 · wk-form4_1780530457.xml · derivative · entry 4 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,970 Underlying: Common Stock · 15,970 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 11,069 | $0.00 Strike: $10.52 | $0.00 |
DisclosureSEC source: 0001628280-26-040579 · wk-form4_1780530457.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,069 Underlying: Common Stock · 11,069 shares Expires 2036-06-01 Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 23,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040579 · wk-form4_1780530457.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 23,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040579 · wk-form4_1780530457.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 21:10 UTC | Anywhere Real Estate Inc. HOUS · Entity 69629 | Disposition to issuerCommon Stock, $0.01 par value | 134,617 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001398987-26-000039 · wk-form4_1767993014.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On January 9, 2026, pursuant to the previously announced Agreement and Plan of Merger, dated as of September 22, 2025 (the Merger Agreement), by and among Anywhere Real Estate Inc. (the Company), Compass, Inc. (Compass), and Velocity Merger Sub, Inc., a wholly owned subsidiary of Compass (Merger Sub), Merger Sub merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly owned subsidiary of Compass. F2 · price: Pursuant to the Merger Agreement, each share of Company common stock, par value $0.01 per share issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), was converted into the right to receive 1.436 fully paid and nonassessable shares (the Exchange Ratio) of class A common stock of Compass (the Compass Shares) and, if applicable, cash in lieu of fractional shares. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU award was canceled and converted into a RSU award in respect of Compass Shares covering that number of Compass Shares equal to the product of (i) the number of shares of Company common stock subject to the award multiplied by (ii) the Exchange Ratio. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 23,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000130 · wk-form4_1748981297.xml · derivative · entry 4 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,077 Underlying: Common Stock · 23,077 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 16,107 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001077183-25-000130 · wk-form4_1748981297.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,107 Underlying: Common Stock · 16,107 shares Expires 2035-06-01 Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 7,160 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000130 · wk-form4_1748981297.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 7,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000130 · wk-form4_1748981297.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 07, 2025 Filed May 8, 2025 20:19 UTC | Anywhere Real Estate Inc. HOUS · Entity 69629 | GrantCommon Stock, $0.01 par value | 43,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001398987-25-000085 · wk-form4_1746735543.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,617 F1 · shares: Represents shares issuable upon settlement of a restricted stock unit award issued under the Third Amended and Restated 2018 Long Term Incentive Plan and vesting on the one year anniversary of the grant date. Read SEC document |
| May 05, 2025 Filed May 7, 2025 20:33 UTC | Paycom Software, Inc. PAYC · Entity 3498 | GrantCommon Stock | 1,099 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-065782 · ownership.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,706 F1 · shares: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan. F2 · balance_after: Includes 2,315 unvested shares of restricted stock. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 7,160 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000159 · wk-form4_1730841106.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,160 Underlying: Common Stock · 7,160 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 5,430 | $0.00 Strike: $13.59 | $0.00 |
DisclosureSEC source: 0001077183-24-000159 · wk-form4_1730841106.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,430 Underlying: Common Stock · 5,430 shares Expires 2034-06-01 Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:01 UTC | Anywhere Real Estate Inc. HOUS · Entity 69629 | GrantCommon Stock, $0.01 par value | 31,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001398987-24-000119 · wk-form4_1715029279.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,490 F1 · shares: Represents shares issuable upon settlement of a restricted stock unit award issued under the Second Amended and Restated 2018 Long Term Incentive Plan and vesting on the one year anniversary of the grant date. Read SEC document |
| April 29, 2024 Filed May 1, 2024 22:15 UTC | Paycom Software, Inc. PAYC · Entity 3498 | GrantCommon Stock | 1,216 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-051453 · ownership.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,607 F1 · shares: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan. F2 · balance_after: Includes 2,005 unvested shares of restricted stock. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 20:14 UTC | Anywhere Real Estate Inc. HOUS · Entity 69629 | PurchaseCommon Stock, $0.01 par value | 8,424 | $5.94 | $49,996.44 |
DisclosureSEC source: 0001398987-24-000076 · wk-form4_1710188051.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,055 Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:05 UTC | Paycom Software, Inc. PAYC · Entity 3498 | GrantCommon Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013166 · doc4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,391 F1 · shares: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan. F2 · balance_after: Includes 789 unvested shares of restricted stock. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:21 UTC | Anywhere Real Estate Inc. HOUS · Entity 69629 | GrantCommon Stock, $0.01 par value | 27,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001398987-23-000113 · wf-form4_168331809752549.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,631 F1 · shares: Represents shares issuable upon settlement of a restricted stock unit award issued under the Second Amended and Restated 2018 Long Term Incentive Plan. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:05 UTC | Paycom Software, Inc. PAYC · Entity 3498 | GrantCommon Stock | 756 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-012079 · doc4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,358 F1 · shares: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan. F2 · balance_after: Represents 1,358 unvested shares of restricted stock. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,656 | $13.25 Strike: $20.75 | $74,942.00 |
DisclosureSEC source: 0001567619-23-001537 · doc1.xml · derivative · entry 6 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,656 shares Expires 2032-01-26 F6 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F6 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F6 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,796 | $12.64 Strike: $21.36 | $73,261.44 |
DisclosureSEC source: 0001567619-23-001537 · doc1.xml · derivative · entry 5 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,796 shares Expires 2031-01-27 F5 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F5 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F5 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,205 | $23.54 Strike: $10.46 | $405,005.70 |
DisclosureSEC source: 0001567619-23-001537 · doc1.xml · derivative · entry 4 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,205 shares Expires 2030-01-29 F4 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,740 | $17.03 Strike: $16.97 | $148,842.20 |
DisclosureSEC source: 0001567619-23-001537 · doc1.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,740 shares Expires 2029-01-04 F3 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | $18.85 Strike: $15.15 | $226,200.00 |
DisclosureSEC source: 0001567619-23-001537 · doc1.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-09-20 F2 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F2 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F2 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerCommon Stock | 10,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-001537 · doc1.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. Read SEC document |
| May 09, 2022 Filed May 10, 2022 20:47 UTC | Paycom Software, Inc. PAYC · Entity 3498 | GrantCommon Stock | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017454 · doc4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F1 · shares: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| May 04, 2022 Filed May 6, 2022 21:28 UTC | Anywhere Real Estate Inc. RLGY · Entity 69629 | GrantCommon Stock, $0.01 par value | 13,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001398987-22-000127 · wf-form4_165187247784667.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,420 F1 · shares: Represents shares issuable upon settlement of a restricted stock unit award issued under the Amended and Restated 2018 Long Term Incentive Plan. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 11:47 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 5,656 | $0.00 Strike: $20.75 | $0.00 |
DisclosureSEC source: 0001127602-22-002354 · form4.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,656 Underlying: Common Stock · 5,656 shares Expires 2032-01-26 F2 · derivative.exercise_date: These options are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 25, 2023. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 11:47 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 3,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002354 · form4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,274 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 25, 2023. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:55 UTC | Anywhere Real Estate Inc. RLGY · Entity 69629 | GrantCommon Stock, $0.01 par value | 9,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001398987-21-000159 · wf-form4_162042092874468.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,638 F1 · shares: Represents shares issuable upon settlement of a restricted stock unit award issued under the Amended and Restated 2018 Long Term Incentive Plan. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:32 UTC | Anywhere Real Estate Inc. RLGY · Entity 69629 | GrantCommon Stock, $0.01 par value | 1,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001398987-21-000116 · wf-form4_161618951894529.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,463 F1 · shares: Represents shares issuable upon settlement of a restricted stock unit award issued under the 2018 Long Term Incentive Plan. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 12:13 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 5,796 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001127602-21-002945 · form4.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,796 Underlying: Common Stock · 5,796 shares Expires 2031-01-27 F2 · derivative.exercise_date: These options are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 26, 2022. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 12:13 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 1,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002945 · form4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,262 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 26, 2022. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:03 UTC | Macy's, Inc. M · Entity 3820 | GrantRestricted Stock Units · Derivative | 52,790 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-20-000091 · primary_doc.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · SVP,Controller/ERM & Int. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,790 Underlying: Common Stock · 52,790 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. F2 · derivative.expiration_date: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 18:23 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 202 | $6.20 | $1,252.40 |
DisclosureSEC source: 0000794367-20-000056 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · SVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927 F2 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations upon the vesting of restricted shares and does not represent a discretionary transaction by the reporting person. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 18:23 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionRestricted Stock Units · Derivative | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-20-000056 · primary_doc.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · SVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342 Underlying: Common Stock · 671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 1-for-1 conversion. F3 · derivative.exercise_date: On April 6, 2018 the reporting person was granted 2,684 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On April 6, 2018 the reporting person was granted 2,684 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 18:23 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionCommon Stock | 671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000794367-20-000056 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · SVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 1-for-1 conversion. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 19:51 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionRestricted Stock Units · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-20-000032 · primary_doc.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · SVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,121 Underlying: Common Stock · 1,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-for-one conversion. F3 · derivative.exercise_date: On March 21, 2019 the reporting person was granted 4,161 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 21, 2019 the reporting person was granted 4,161 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 19:51 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 422 | $4.92 | $2,075.23 |
DisclosureSEC source: 0000794367-20-000032 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · SVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 F2 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations upon the vesting of restricted shares and does not represent a discretionary transaction by the reporting person. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 19:51 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionCommon Stock | 1,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000794367-20-000032 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · SVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-for-one conversion. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 13:55 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 1,550 | $6.02 | $9,331.00 |
DisclosureSEC source: 0001127602-20-011012 · form4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,717 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 17:23 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 6,556 | $12.72 | $83,416.58 |
DisclosureSEC source: 0000794367-20-000024 · primary_doc.xml · nonDerivative · entry 3 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:23 UTC | Macy's, Inc. M · Entity 3820 | Tax withholdingCommon Stock | 416 | $13.23 | $5,503.68 |
DisclosureSEC source: 0000794367-20-000024 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,396 F2 · shares: Withholding by Macy's, Inc. of 416 shares of common stock to satisfy reporting person's tax withholding obligations in connection with the vesting of accrued dividends on performance restricted stock units and delivery of common stock on February 28, 2020. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:23 UTC | Macy's, Inc. M · Entity 3820 | GrantCommon Stock | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-20-000024 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,812 F1 · shares: Settlement of performance restricted stock units granted in March 2017 following a 3-year (fiscal 2017-2019) performance period. Number includes 1,256 dividend shares accrued during the performance period. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:36 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 17,205 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001127602-20-002840 · form4.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,205 Underlying: Common Stock · 17,205 shares Expires 2030-01-30 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:36 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 3,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-002840 · form4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 19:02 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionRestricted Stock Units · Derivative | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-19-000042 · primary_doc.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013 Underlying: Common Stock · 671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-for-one conversion. F2 · derivative.exercise_date: On April 6, 2018, the reporting person was granted 2,684 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On April 6, 2018, the reporting person was granted 2,684 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 19:02 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 671 | $25.69 | $17,235.10 |
DisclosureSEC source: 0000794367-19-000042 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 19:02 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionCommon Stock | 671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000794367-19-000042 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-for-one conversion. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 20:06 UTC | Macy's, Inc. M · Entity 3820 | GrantRestricted Stock Units · Derivative | 4,161 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-19-000019 · primary_doc.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 Underlying: Common Stock · 4,161 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Macy's, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. F3 · derivative.expiration_date: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.